Advertisement

Neonatology pp 677-691 | Cite as

Safety of Medications During Pregnancy and Breastfeeding: Infants of Drug-Addicted Mothers

  • Karel Allegaert
  • Tim van Mieghem
  • John N. van den Anker
Reference work entry

Abstract

Any decision on maternal pharmacotherapy should be balanced, comparing maternal and fetal/neonatal outcome to withholding any treatment. This is because there is a relevant body of evidence that uncontrolled maternal conditions also affect fetal outcome. The same holds true for breastfeeding.

Drugs are not thoroughly evaluated for use during pregnancy or breastfeeding. Knowledge on safety of drugs exposure during fetal and neonatal (breastfeeding) life is limited. Pregnancy category classifications for drugs are currently used, but have their limitations. Pregnancy exposure registries to build knowledge have been implemented in the recently revised version of the FDA labelling guidelines (Pregnancy and Lactation Labeling Final Rule).

Suggestive indicators of “likely safe during breastfeeding” are (i) drugs commonly administered to infants, (ii) drugs that are not absorbed following oral administration, (iii) not excreted into human milk, and finally (iv) drug considered safe during pregnancy, since fetal exposure is generally longer and more extensive. Aspects of opioids, benzodiazepines, and anti-epileptics use during fetal life or via breastfeeding have been discussed to illustrate the concepts of pregnancy-related clinical pharmacology, followed by a focused discussion on neonatal abstinence syndromes. We hereby aim to provide the practicing clinician with some guidance and sources of information.

Keywords

Antiepileptic drugs Benzodiazepines Breastfeeding Drug labeling LactMed Maternal–fetal pharmacotherapy Motherisk program Neonatal abstinence syndrome (NAS) Neonatal withdrawal syndromes Selective serotonin reuptake inhibitors (SSRIs) 

Notes

Acknowledgments

Karel Allegaert is supported by the Fund for Scientific Research, Flanders (fundamental clinical investigatorship 1800214 N), and the research activities are further facilitated by the agency for innovation by Science and Technology in Flanders (IWT) through the SAFEPEDRUG project (IWT/SBO 130033). John van den Anker is supported by NIH (K24DA027992, R01HD048689, U54HD071601) and the European Commission (TINN [223614], TINN2 [260908]. NEUROSIS [223060]).

References

  1. Allegaert K, van den Anker JN (2015) Maternal analgosedation and breastfeeding: guidance for the pediatrician. JPNIM 4, e04117Google Scholar
  2. Allegaert K, Langhendries JP, van den Anker JN (2013) Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 172(4):429–435CrossRefGoogle Scholar
  3. Amant F, Han SN, Gziri MM et al (2015) Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol 29:741–753CrossRefGoogle Scholar
  4. Anderson PO, Pochop SL, Manoquerra AS (2003) Adverse drug reactions in breastfed infants: less than imagined. Clin Pediatr (Phila) 42:325–340CrossRefGoogle Scholar
  5. Asti L, Magers JS, Keels E et al (2015) A quality improvement project to reduce length of stay for neonatal abstinence syndrome. Pediatrics 135:e1494–e1500CrossRefGoogle Scholar
  6. Bada HS, Sithisam T, Gibson J et al (2015) Morphine versus clonidine for neonatal abstinence syndrome. Pediatrics 135:e383–e391CrossRefGoogle Scholar
  7. Berlin CM Jr, van den Anker JN (2013) Safety during breastfeeding: drugs, foods, environmental chemicals, and maternal infections. Semin Fetal Neonatal Med 18:13–18CrossRefGoogle Scholar
  8. Briggs GG, Polifka JE, Wisner KL et al (2015) Should pregnant women be included in phase IV clinical drug trials? Am J Obstet Gynecol 213:810–815CrossRefGoogle Scholar
  9. Cole AP, Hailey DM (1975) Diazepam and active metabolite in breast milk and their transfer to the neonate. Arch Dis Child 50:741–742CrossRefGoogle Scholar
  10. Creanga AA, Sabel JC, Ko JY et al (2012) Maternal drug use and its effect on neonates: a population-based study in Washington State. Obstet Gynecol 119:924–933CrossRefGoogle Scholar
  11. De Wildt SN, Kearns GL, Hop WC et al (2002) Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 53:390–392CrossRefGoogle Scholar
  12. DeVane CL (2015) An epidemic of opioid prescriptions. Pharmacotherapy 35:241–242CrossRefGoogle Scholar
  13. Dow K, Ordean A, Murphy-Oikonen J et al (2012) Neonatal abstinence syndrome clinical practice guidelines for Ontario. J Popul Ther Clin Pharmacol 19:e488–e506PubMedGoogle Scholar
  14. Feghali MN, Mattison DR (2011) Clinical therapeutics in pregnancy. J Biomed Biotechnol 2011:783528CrossRefGoogle Scholar
  15. Gadot Y, Koren G (2015) The use of antidepressants in pregnancy: focus on maternal risks. J Obstet Gynaecol Can 37:56–63CrossRefGoogle Scholar
  16. Genung V (2013) Psychopharmacology column: a review of psychotropic medication lactation risks for infants during breastfeeding. J Child Adolesc Psychiatr Nurs 26:214–219CrossRefGoogle Scholar
  17. Hendrickson RG, McKeown NJ (2012) Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol 50:1–14CrossRefGoogle Scholar
  18. Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics (2012) Neonatal drug withdrawal. Pediatrics 129:e540–e560CrossRefGoogle Scholar
  19. Ito S, Blajchman A, Stephenson M, Eliopoloulos C, Koren G (1993) Prospective follow up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 168:1393–1399CrossRefGoogle Scholar
  20. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368:704CrossRefGoogle Scholar
  21. Lam J, Kelly L, Ciszkowski C et al (2012) Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr 160:33.e2–37.e2CrossRefGoogle Scholar
  22. Lefevere J, Allegaert K (2015) Question: is breastfeeding useful in the management of neonatal abstinence syndrome? Arch Dis Child 100:414–415CrossRefGoogle Scholar
  23. MacMullen NJ, Dulski LA, Blobaum P (2014) Evidence-based interventions for neonatal abstinence syndrome. Pediatr Nurs 40:165–172PubMedGoogle Scholar
  24. Marsot A, Brevaut-Malaty V, Vialet R (2014) Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. Fundam Clin Pharmacol 28:465–471CrossRefGoogle Scholar
  25. Meador KJ, Baker GA, Browning N et al (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360:1597–1605CrossRefGoogle Scholar
  26. Meador KJ, Baker GA, Browning N et al (2014) Breastfeeding in children of women taking antiepileptic drugs. Cognitive outcomes at age 6 years. JAMA Pediatr 168:729–736CrossRefGoogle Scholar
  27. Ng CM, Dombrowsky E, Lin H et al (2015) Population pharmacokinetic model of sublingual buprenorphine in neonatal abstinence syndrome. Pharmacotherapy 35(7):670–680CrossRefGoogle Scholar
  28. Nitsun M, Szokol JW, Saleh HJ et al (2006) Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. Clin Pharmacol Ther 79:549–557CrossRefGoogle Scholar
  29. O’Donnell M, Nassar N, Leonard H et al (2009) Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics 123:e614–e621CrossRefGoogle Scholar
  30. Ornoy A, Koren G (2014) Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy. Semin Fetal Neonatal Med 19:188–194CrossRefGoogle Scholar
  31. Patrick SW, Schumacher RE, Benneyworth BD et al (2012) Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 307:1934–1940CrossRefGoogle Scholar
  32. Patrick SW, Davis MM, Lehman CU, Cooper WO (2015) Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 35:650–655CrossRefGoogle Scholar
  33. Pavek P, Ceckova M, Staud F (2009) Variation of drug kinetics in pregnancy. Curr Drug Metab 10:520–529CrossRefGoogle Scholar
  34. Pressler RM, Mangum B (2013) Newly emerging therapies for neonatal seizures. Semin Fetal Neonatal Med 18:216–223CrossRefGoogle Scholar
  35. Ramoz LL, Patel-Shori NM (2014) Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy 34:389–395CrossRefGoogle Scholar
  36. Reefhuis J, Devine O, Friedman JM et al (2015) Specific SSRIs and birth defects bayesian analysis to interpret new data in the context of previous reports. BMJ 351:h3190Google Scholar
  37. Rivers CM, Olsen D, Nelson LS (2012) Breastfeeding and oxycodone. J Pediatr 161:174CrossRefGoogle Scholar
  38. Rowe H, Baker T, Hale TW (2013) Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am 60:275–294CrossRefGoogle Scholar
  39. Saadeh RJ (2012) The Baby-Friendly Hospital Initiative 20 years on: facts, progress, and the way forward. J Hum Lact 28:272–275CrossRefGoogle Scholar
  40. Sachs HC, Committee on Drugs (2013) The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 132:e796–e809CrossRefGoogle Scholar
  41. Salman S, Sy SK, Ilett KF, Page-Sharp M, Paech MJ (2011) Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. Eur J Clin Pharmacol 67:899–908CrossRefGoogle Scholar
  42. Sistonen J, Madadi P, Ros CJ et al (2012) Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 91:692–699CrossRefGoogle Scholar
  43. Siu A, Robinson CA (2014) Neonatal abstinence syndrome: essentials for the practitioner. J Pediatr Pharmacol Ther 19:147–155PubMedPubMedCentralGoogle Scholar
  44. Thomas SH, Yates LM (2012) Prescribing without evidence – pregnancy. Br J Clin Pharmacol 74:691–697CrossRefGoogle Scholar
  45. Turner SD, Gomes T, Camacho X et al (2015) Neonatal opioid withdrawal and antenatal opioid prescribing. CAMJ Open 13:E55–E61CrossRefGoogle Scholar
  46. Van den Anker JN (2012) Is it safe to use opioids for obstetric pain while breastfeeding? J Pediatr 160:4–6CrossRefGoogle Scholar
  47. Veiby G, Engelsen BA, Gilhus NE (2013) Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol 70:1367–1374CrossRefGoogle Scholar
  48. Veiby G, Bjork M, Engelsen BA, Gilhus NE (2015) Epilepsy and recommendations for breastfeeding. Seizure 28:57–65CrossRefGoogle Scholar
  49. Verreault N, Da Costa D, Marchand A et al (2014) Rates and risk factors associated with depressive symptoms during pregnancy and with postpartum onset. J Psychosom Obstet Gynaecol 35:84–91CrossRefGoogle Scholar
  50. Wachman EM, Hayes MJ, Brown MS et al (2013) Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 309:1821–1827CrossRefGoogle Scholar
  51. Zaijcek A, Giacoia GP (2007) Obstetric clinical pharmacology: coming of age. Clin Pharmacol Ther 81:481–482CrossRefGoogle Scholar
  52. Zimmermann-Baer U, Nötzi U, Rentsch K, Bucher HU (2010) Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5–6 in non-addicted infants. Addiction 105:524–528CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Karel Allegaert
    • 1
    • 2
    • 6
  • Tim van Mieghem
    • 2
    • 3
  • John N. van den Anker
    • 4
    • 5
    • 6
  1. 1.Neonatal Intensive Care UnitUniversity Hospitals LeuvenLeuvenBelgium
  2. 2.Department of Development and RegenerationKU LeuvenLeuvenBelgium
  3. 3.Obstetrics and GynecologyUniversity Hospitals LeuvenLeuvenBelgium
  4. 4.Division of Pediatric Clinical PharmacologyChildren’s National Health SystemWashingtonUSA
  5. 5.Departments of Pediatrics, Integrative Systems Biology, Pharmacology and PhysiologyGeorge Washington University, School of Medicine and Health SciencesWashingtonUSA
  6. 6.Intensive Care and Department of Pediatric SurgeryErasmus MC – Sophia Children’s HospitalRotterdamThe Netherlands

Personalised recommendations